Biotechnology

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

The successful Hong Kong IPO of a LanzaTech joint venture isn't just a financial win; it's a market validation for turning pollution into valuable products.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

A Florida biotech is using a novel gene therapy to correct aging-related errors. But the real story is its funding: a decentralized, crypto-style model.

As Insulet unveils pivotal data, a deeper look reveals a strategy to not just improve tech, but to fundamentally change the daily reality of diabetes.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.

A strategic shift in research funding is backing novel science that targets glial cells, not just neurons. This could be a critical turning point in the fight against ALS.

Scispot's Series A targets the messy 'coordination gap' in labs. It's a bet that before we get self-driving labs, we must first fix the data pipes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

Beyond dividends, Stevanato Group's recent shareholder meeting signals a deeper shift in corporate governance, modernizing for stability and trust.

As Alkermes prepares for a key investor conference, it's not just about numbers. It's about a bold new strategy in sleep medicine, a billion-dollar pipeline, and a new CEO.

As CEO Reshma Kewalramani takes the stage, investors will look for clues on how Vertex plans to pivot from CF dominance to a multi-franchise powerhouse.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.